
{
  "Company Overview": {
    "Name": "Caplin Point Laboratories Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Formulations",
    "Business Description": "Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. Presently, the company has a very wide portfolio of pharma products with 4,000+ registered products, 650+ formulations and presence in 36 therapeutic segments. It has minimal reliance for revenues on a single product/ therapeutic segment.",
    "Market Position": "Part of Nifty 500, Multicap 50:25:25, BSE 250, SmallCap Index, BSE 400 MidSmallCap Index, BSE SmallCap, BSE Allcap, Nifty MidSmallcap 400, Nifty Smallcap 250, Nifty Total Market, BSE 500, BSE Healthcare, Nifty 500"
  },
  "Financial Metrics": {
    "Market Cap": "₹ 17,570 Cr.",
    "Current Price": "₹ 2,311",
    "High/Low": "₹ 2,540 / ₹ 1,221",
    "P/E Ratio": "35.6",
    "Book Value": "₹ 334",
    "Dividend Yield": "0.22 %",
    "ROCE": "26.5 %",
    "ROE": "24.2 %",
    "Face Value": "₹ 2.00"
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [304, 326, 339, 346, 359, 372, 389, 395, 410, 436, 453, 459, 483],
      "Expenses": [202, 225, 239, 244, 253, 263, 265, 269, 273, 293, 308, 307, 318],
      "Operating Profit": [101, 101, 100, 102, 106, 109, 124, 127, 137, 142, 145, 152, 165],
      "OPM %": ["33%", "31%", "29%", "30%", "29%", "29%", "32%", "32%", "34%", "33%", "32%", "33%", "34%"],
      "Other Income": [8, 10, 12, 14, 16, 14, 11, 12, 21, 17, 17, 19, 21],
      "Interest": [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],
      "Depreciation": [12, 12, 11, 11, 11, 11, 11, 11, 12, 14, 16, 16, 17],
      "Profit before tax": [98, 99, 100, 105, 110, 112, 124, 127, 146, 145, 146, 154, 168],
      "Tax %": ["21%", "20%", "19%", "18%", "17%", "13%", "18%", "18%", "20%", "18%", "17%", "19%", "22%"],
      "Net Profit": [77, 79, 81, 86, 92, 97, 101, 104, 116, 120, 121, 125, 131],
      "EPS in Rs": [9.91, 9.89, 10.43, 11.21, 12.09, 12.84, 13.45, 13.62, 15.13, 15.43, 16.01, 16.31, 17.21]
    },
    "Annual Results": {
      "Sales": [127, 173, 252, 239, 402, 540, 649, 863, 1061, 1269, 1467, 1694, 1831],
      "Expenses": [105, 137, 192, 175, 276, 345, 417, 603, 732, 874, 1025, 1142, 1227],
      "Operating Profit": [22, 36, 60, 64, 125, 195, 232, 260, 329, 395, 442, 552, 604],
      "OPM %": ["18%", "21%", "24%", "27%", "31%", "36%", "36%", "30%", "31%", "31%", "30%", "33%", "33%"],
      "Other Income": [2, 4, 3, 4, 10, 13, 19, 41, 23, 38, 55, 66, 74],
      "Interest": [1, 1, 1, 0, 1, 1, 1, 0, 2, 1, 1, 1, 1],
      "Depreciation": [2, 4, 8, 7, 13, 19, 23, 32, 37, 47, 45, 53, 63],
      "Profit before tax": [22, 36, 53, 60, 121, 188, 227, 269, 314, 386, 451, 564, 614],
      "Tax %": ["37%", "27%", "23%", "24%", "21%", "23%", "22%", "20%", "20%", "20%", "16%", "18%", "18%"],
      "Net Profit": [14, 26, 41, 46, 96, 145, 177, 215, 251, 308, 377, 461, 497],
      "EPS in Rs": [1.85, 3.42, 5.43, 6.05, 12.65, 19.15, 23.35, 28.42, 32.03, 39.56, 49.57, 60.19, 64.96]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth (10 Years)": "30%",
      "Compounded Sales Growth (5 Years)": "21%",
      "Compounded Sales Growth (3 Years)": "17%",
      "Compounded Sales Growth (TTM)": "17%",
      "Compounded Profit Growth (10 Years)": "42%",
      "Compounded Profit Growth (5 Years)": "21%",
      "Compounded Profit Growth (3 Years)": "24%",
      "Compounded Profit Growth (TTM)": "18%",
      "Stock Price CAGR (10 Years)": "40%",
      "Stock Price CAGR (5 Years)": "49%",
      "Stock Price CAGR (3 Years)": "45%",
      "Stock Price CAGR (1 Year)": "64%"
    },
    "Liquidity Ratios": {
      "Debtor Days": [2, 0, 8, 12, 30, 85, 90, 97, 96, 91, 98, 117],
      "Inventory Days": [45, 35, 37, 57, 44, 44, 47, 210, 139, 149, 159, 183],
      "Days Payable": [111, 112, 112, 168, 155, 144, 76, 57, 68, 102, 84, 106],
      "Cash Conversion Cycle": [-63, -77, -67, -99, -81, -16, 61, 251, 166, 138, 173, 194],
      "Working Capital Days": [-176, -181, -128, -114, -29, 47, 104, 167, 152, 166, 146, 166]
    },
    "Profitability Ratios": {
      "ROCE %": [52, 64, 68, 62, 68, 63, 45, 33, 28, 28, 26, 26],
      "ROE (10 Years)": "29%",
      "ROE (5 Years)": "26%",
      "ROE (3 Years)": "25%",
      "ROE (Last Year)": "24%"
    },
    "Valuation Ratios": {
      "Market Cap / Sales": null, 
      "EV / EBITDA": null,
      "Price to Book": null
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Torrent Pharma.", "CMP": 3437.00, "P/E": 66.84, "Mar Cap": 116318.47, "Div Yld": 0.81, "NP Qtr": 453.00, "Qtr Profit Var": 17.36, "Sales Qtr": 2889.00, "Qtr Sales Var": 8.61, "ROCE": 23.16},
      {"Name": "Ajanta Pharma", "CMP": 2866.45, "P/E": 40.92, "Mar Cap": 35805.43, "Div Yld": 1.26, "NP Qtr": 216.48, "Qtr Profit Var": 10.84, "Sales Qtr": 1186.64, "Qtr Sales Var": 15.38, "ROCE": 31.60},
      {"Name": "Gland Pharma", "CMP": 1772.30, "P/E": 42.22, "Mar Cap": 29198.95, "Div Yld": 1.13, "NP Qtr": 163.53, "Qtr Profit Var": -15.74, "Sales Qtr": 1405.83, "Qtr Sales Var": 2.36, "ROCE": 13.58},
      {"Name": "ERIS Lifescience", "CMP": 1380.30, "P/E": 54.12, "Mar Cap": 18789.92, "Div Yld": 0.00, "NP Qtr": 96.35, "Qtr Profit Var": -25.12, "Sales Qtr": 741.17, "Qtr Sales Var": 46.68, "ROCE": 11.27},
      {"Name": "Caplin Point Lab", "CMP": 2311.45, "P/E": 35.62, "Mar Cap": 17569.72, "Div Yld": 0.22, "NP Qtr": 130.81, "Qtr Profit Var": 13.87, "Sales Qtr": 483.10, "Qtr Sales Var": 17.81, "ROCE": 26.46},
      {"Name": "Sai Life", "CMP": 703.65, "P/E": 176.75, "Mar Cap": 14635.18, "Div Yld": 0.00, "NP Qtr": 28.01, "Qtr Profit Var": 675.29, "Sales Qtr": 5.13, "Qtr Sales Var": 10.57, "ROCE": 10.57},
      {"Name": "Marksans Pharma", "CMP": 304.90, "P/E": 39.92, "Mar Cap": 13816.96, "Div Yld": 0.20, "NP Qtr": 97.76, "Qtr Profit Var": 15.80, "Sales Qtr": 641.92, "Qtr Sales Var": 20.83, "ROCE": 20.61}
    ],
    "Median": {
      "CMP": 372.42,
      "P/E": 36.33,
      "Mar Cap": 520.58,
      "Div Yld": 0.14,
      "NP Qtr": 7.85,
      "Qtr Profit Var": 10.84,
      "Sales Qtr": 69.66,
      "Qtr Sales Var": 10.68,
      "ROCE": 13.41
    }
  },
  "Other Insights": {
    "Pros": [
      "Company has reduced debt.",
      "Company is almost debt free.",
      "Company has delivered good profit growth of 21.1% CAGR over last 5 years",
      "Company has a good return on equity (ROE) track record: 3 Years ROE 25.3%",
      "Company's median sales growth is 23.0% of last 10 years"
    ],
    "Cons": [
      "The pros and cons are machine generated.",
      "Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis."
    ],
    "Notes on Shareholding Pattern": [
      "The classifications might have changed from Sep'2022 onwards.",
      "The new XBRL format added more details from Sep'22 onwards.",
      "Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.",
      "Click on the line-items to see the names of individual entities."
    ],
    "Announcements": [
      "16 Dec - Caplin Steriles receives USFDA approval for eye drops.",
      "12 Dec - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate",
      "9 Dec - Analyst/Institutional Investor meeting scheduled on December 12, 2024.",
      "15 Nov - Issuance of duplicate share certificates requested.",
      "14 Nov - Transcript of Q2 FY 2024-25 earnings call available."
    ]
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [68.91, 68.89, 68.88, 68.88, 68.80, 70.66, 70.63, 70.62, 70.62, 70.62, 70.56, 70.56],
      "FIIs": [2.11, 2.07, 2.03, 2.15, 2.24, 2.36, 2.68, 3.09, 2.84, 3.33, 3.38, 3.71],
      "DIIs": [1.22, 1.25, 1.12, 1.12, 1.12, 0.64, 0.27, 0.21, 0.43, 1.08, 1.49, 1.83],
      "Public": [27.76, 27.78, 27.97, 27.85, 27.84, 26.33, 26.44, 26.08, 26.11, 24.95, 24.59, 23.93]
    },
    "Yearly": {
      "Promoters": [69.06, 69.04, 69.04, 69.03, 69.03, 68.89, 70.66, 70.62, 70.56],
      "FIIs": [5.19, 6.21, 7.32, 4.43, 0.68, 2.07, 2.36, 3.33, 3.71],
      "DIIs": [0.46, 0.09, 0.01, 0.04, 1.28, 1.25, 0.64, 1.08, 1.83],
      "Public": [25.29, 24.66, 23.63, 26.50, 29.01, 27.78, 26.33, 24.95, 23.93]
    }
  }
}
